"); //-->
PioglitazoneDoxycycline Differin Tadalafil |
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
|
Atgins Diet, Low Carb information, |
||||||||||||||||||||||||||||||||||||||||||||||
|
ond Low Carb recipes. |
||||||||||||||||||||||||||||||||||||||||||||||
|
Riad my personal Low Carb story |
||||||||||||||||||||||||||||||||||||||||||||||
|
ond Low Carb dieting tips. |
||||||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||
TiazacHowever, medications are often necessary in order to help you get back to sleep, or even sleep through bladder interruptions during the night. Drug Name NIMOTOP NORVASC PLENDIL PROCARDIA XL SULAR taztia xt TIAZAC verapamil hcl VERELAN CARDIOTONICS digitek digoxin LANOXICAPS LANOXIN CARDIOVASCULAR AGENTS - MISC. BIDIL CADUET REVATIO TRACLEER CEPHALOSPORINS CECLOR CEDAX cefaclor cefadroxil cefdinir cefprozil CEFTIN ceftriaxone sodium cefuroxime axetil CEFZIL cephalexin MAXIPIME OMNICEF ROCEPHIN SPECTRACEF SUPRAX VANTIN 27. Who can take nsaids only your doctor can determine the right medication for you. Cassiebel , i take benicar 40 and tiazac 18 tiazac and cardizem are both brand names of diltiazem. 3.4 STEM CELLS AND IMMUNOSUPPRESSIVE DRUG. Many of the drugs used to treat asthma are in the form of inhaled aerosols. The drugs, as well as the devices, vary significantly in their use. The most commonly used devices for inhaling aerosolised drugs are the metered-dose inhaler MDI ; , the small-volume nebuliser SVN ; and the dry-powder inhaler DPI and tobradex. All services a-z drug list drugs & medications diseases & conditions news & articles pill identifier interactions checker drug image search new drug approvals new drug applications fda drug alerts clinical trial results patient care notes medical encyclopedia medical dictionary medical videos - community forums for professionals veterinary drugs drug imprint codes contact us news feeds advertise here recent searches fioricet apokyn tiazac advate sprycel allegra clonazepam prialt sanctura flulaval emtriva duetact viagra xenical naprosyn geodon actiq prevnar orencia clomid triaminic tadalafil veregen lexiva yaz recently approved exelon patch endometrin exforge nuvigil letairis extina divigel torisel xyzal lybrel more. The group of drugs known as antiplatelet agents received a class 1 recommendation in the guidelines and toprol, for example, blood pressure. Tiazac therapy
Do not take the following medicine if you are taking REYATAZ atazanavir sulfate ; and NORVIR together. VFEND voriconazole ; . The following medicines may require your healthcare provider to monitor your therapy more closely: CIALIS tadalafil ; , LEVITRA vardenafil ; , or VIAGRA sildenafil ; . REYATAZ may increase the chances of serious side effects that can happen with CIALIS, LEVITRA, or VIAGRA. Do not use CIALIS, LEVITRA, or VIAGRA while you are taking REYATAZ unless your healthcare provider tells you it is okay. LIPITOR atorvastatin ; . There is an increased chance of serious side effects if you take REYATAZ with this cholesterol-lowering medicine. Medicines for abnormal heart rhythm: CORDARONE amiodarone ; , lidocaine, quinidine also known as CARDIOQUIN, QUINIDEX, and others ; . VASCOR bepridil, used for chest pain ; . COUMADIN warfarin ; . Tricyclic antidepressants such as ELAVIL amitriptyline ; , NORPRAMIN desipramine ; , SINEQUAN doxepin ; , SURMONTIL trimipramine ; , TOFRANIL imipramine ; , or VIVACTIL protriptyline ; . Medicines to prevent organ transplant rejection: SANDIMMUNE or NEORAL cyclosporin ; , RAPAMUNE sirolimus ; , or PROGRAF tacrolimus ; . The antidepressant trazodone DESYREL and others ; . Fluticasone propionate ADVAIR, FLONASE, FLOVENT ; , given by nose or inhaled to treat allergic symptoms or asthma. Your doctor may choose not to keep you on fluticasone, especially if you are also taking NORVIR. The following medicines may require a change in the dose or dose schedule of either REYATAZ or the other medicine: FORTOVASE, INVIRASE saquinavir ; . NORVIR ritonavir ; . SUSTIVA efavirenz ; . Antacids or buffered medicines. VIDEX didanosine ; . VIREAD tenofovir disoproxil fumarate ; . MYCOBUTIN rifabutin ; . Calcium channel blockers such as CARDIZEM or TIAZAC diltiazem ; , COVERA-HS or ISOPTIN SR verapamil ; , and others. BIAXIN clarithromycin ; . Medicines for indigestion, heartburn, or ulcers such as AXID nizatidine ; , PEPCID AC famotidine ; , TAGAMET cimetidine ; , or ZANTAC ranitidine ; . Women who use birth control pills or "the patch" should choose a different kind of contraception. REYATAZ may affect the safety and effectiveness of birth control pills or the patch. Talk to your healthcare provider about choosing an effective contraceptive. Remember: 1. Know all the medicines you take. 2. Tell your healthcare provider about all the medicines you take. 3. Do not start a new medicine without talking to your healthcare provider. How should I store REYATAZ? Store REYATAZ Capsules at room temperature, 59 to 86 F not store this medicine in a damp place such as a bathroom medicine cabinet or near the kitchen sink. Keep your medicine in a tightly closed container. Throw away REYATAZ when it is outdated or no longer needed by flushing it down the toilet or pouring it down the sink. General information about REYATAZ This medicine was prescribed for your particular condition. Do not use REYATAZ for another condition. Do not give REYATAZ to other people, even if they have the same symptoms you have. It may harm them. Keep REYATAZ and all medicines out of the reach of children and pets. This summary does not include everything there is to know about REYATAZ. Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Remember no written summary can replace careful discussion with your healthcare provider. If you would like more information, talk with your healthcare provider or you can call 1-800-321-1335. What are the ingredients in REYATAZ? Active Ingredient: atazanavir sulfate Inactive Ingredients: Crospovidone, lactose monohydrate milk sugar ; , magnesium stearate, gelatin, FD&C Blue #2, titanium dioxide, black iron oxide, red iron oxide, and yellow iron oxide. VIDEX and REYATAZ are registered trademarks of Bristol-Myers Squibb Company. COUMADIN and SUSTIVA are registered trademarks of Bristol-Myers Squibb Pharma Company. DESYREL is a registered trademark of Mead Johnson and Company. Other brands listed are the trademarks of their respective owners and are not trademarks of Bristol-Myers Squibb Company and triamterene.
Prescriptions for hypnotics and anxiolytics should only be issued for short-term relief no longer than 4 weeks ; of severe insomnia or anxiety. Benzodiazepines may be classified according to their duration of action which is an important consideration when selecting the most appropriate drug. Short-acting benzodiazepines have a higher potential for abuse and withdrawal phenomena are more common. Of the benzodiazepines listed below their relative durations of action are: long-acting intermediate-acting short-acting.
ADVANTAGES "The alternative to incision" Provides tubal sterilization in physician's or ambulatory surgery office average operating time: 13 to 35 minutes ; It is the woman's own tissue plus the implant that causes tubal occlusion No major change in a woman's menstrual cycles No failures among 453 women relying on Essure for one year following confirmation of tubal blockage at 3 months by hysteroscopy; 99.8% effective 2 years There is no need for conscious sedation or general anesthesia nonsteriodal premedication is strongly recommended to prevent tubal spasm ; In clinical trial, Australia, Europe, and the U.S. ; 92% of women returned to work in one day, most resumed normal activities the same day as the procedure May be preferred for obese women, women with abdominal adhesions, or women with risk factors for anesthesia DISADVANTAGES: Requires specialized training and equipment Hysterosaplingogram must be done at 3 months to confirm blockage. Until that time, couple must use another contraceptive. Procedure designed for interval sterilization. It is not to be used at Cesarean section or immediately postpartum [Bullagh, 2003] Luteal pregnancies occured in 4 of 466 women in spite of negative urine pregnancy tests on the day of the procedure It may not be possible to visualize both tubal ostia this occurs about 2% of the time ; May require more than one operative procedure In only 446 of 518 women 86.1% ; could devices be introduced into both tubes at the time of the first procedure due to lateral tubes, tubal spasm or tube already not patent Tubal spasm may occur Expulsion of one or both devices 14 of 466 successful procedures or 3.0% ; Perforation of the uterus occured during 4 of 466 procedures This form of sterilization cannot be reversed and trimox.
The ccbs used in preventing migraine headaches are diltiazem cardizem, dilacor, tiazac ; , verapamil calan, verelan, isoptin ; , and nimodipine.
Infliximab Remicade ; is a drug used as a second line therapy for some patients with Crohn's disease or rheumatoid arthritis. This drug acts by reducing inflammation. It is usually administered via intravenous infusion in the physician's office, outpatient setting or infusion center. Infliximab is typically administered initially in a three-dose induction regimen every 3 weeks, followed by maintenance therapy every 8 weeks and triphasil.
Upon adoption of SFAS 123R, the Company recognized the stock-based compensation expense associated with awards granted after January 1, 2006 and the unamortized compensation expense related to the unvested portion of 2005 awards outstanding as of January 1, 2006. During the year ended December 31, 2006, the Company recognized stock-based compensation expense of , 328 for stock options and 0 for awards of restricted stock using the straight-line method. Upon the adoption of SFAS 123R, the Company reclassified deferred stock-based compensation expense of , 052 to additional paid-in-capital. No cumulative catch-up adjustment related to forfeitures was recorded. As a result of the adoption of SFAS 123R, loss from operations, net loss and net loss per basic and diluted share for the year ended December 31, 2006 increased by , 389, , 389 and ##TEXT##.12, respectively. The adoption of SFAS 123R had no effect on the statement of cash flows due to the Company's net loss position. Stock Options Granted to Non-Employees The Company accounts for transactions in which services are received from non-employees in exchange for equity instruments based on the fair value of such services received or of the equity instruments issued, whichever is more reliably measured, in accordance with SFAS 123 and the Emerging Issues Task Force EITF Issue No. 96-18, Accounting for Equity Instruments that Are Issued to Other than Employees for Acquiring, or in Conjunction with Selling, Goods or Services. Income Taxes Deferred taxes are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. Valuation allowances are provided, if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Recently Issued Accounting Pronouncements In September 2006, the FASB issued SFAS No. 157, "Fair Value Measurements, " or SFAS No. 157. SFAS No. 157 defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles and expands disclosures about fair value measurements. SFAS No. 157 codifies the definition of fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, clarifies the principle that fair value should be based on the assumptions market participants would use when pricing the asset or liability and establishes a fair value hierarchy that prioritizes the information used to develop those assumptions. SFAS No. 157 is effective for fiscal years beginning after December 15, 2006. The Company does not currently believe that adoption will have a material impact on its results of operations, financial position or cash flows. In June 2006, the FASB issued FASB Interpretation No. 48, "Accounting for Uncertainty in Income Taxes--an Interpretation of FASB Statement No. 109." This interpretation clarifies the accounting for, because cartia xt. Tiazac medicineTiazac dosage2001.150 This certification was followed by an infringement suit on April 5, 2001 and the FDA granted another 30-month stay as a result of the new suit.151 After Andrx's unsuccessful attempt to de-list the '463 patent, the FTC issued a complaint against Biovail, followed shortly by a consent decree. In the consent decree, Biovail agreed to dismiss with prejudice all claims for enforcement of the '463 patent within five days of the consent decree, followed by divestment of all exclusive licenses to the '463 patent within 30 days.152 Biovail also was barred from seeking any more 30month stays of Andrx's ANDA approval.153 The FTC also required notice prior to the acquisition of any patent or license for the purposes of listing that patent in the Orange Book.154 It is noteworthy that the FTC sought divestment of these licenses; perhaps this reflects the FTC's view that the patents did not cover Tiazac or feared additional anticompetitive uses of the licenses. 100: Powell FC, O'Kane M. Management of pyoderma gangrenosum. Dermatol Clin. 2002 Apr; 20 2 ; : 347-55, viii. Review. PMID: 12120448 [PubMed - indexed for MEDLINE] 101: Newton KM, Buist DS, Keenan NL, Anderson LA, LaCroix AZ. Use of alternative therapies for menopause symptoms: results of a population-based survey. Obstet Gynecol. 2002 Jul; 100 1 ; : 18-25. Erratum in: Obstet Gynecol 2003 Jan; 101 1 ; : 205. PMID: 12100799 [PubMed - indexed for MEDLINE] 102: Warren MP, Shortle B, Dominguez JE. Use of alternative therapies in menopause. Best Pract Res Clin Obstet Gynaecol. 2002 Jun; 16 3 ; : 411-48. Review. PMID: 12099671 [PubMed - indexed for MEDLINE] 103: Vanina Y, Podolskaya A, Sedky K, Shahab H, Siddiqui A, Munshi F, Lippmann S. Body weight changes associated with psychopharmacology. Psychiatr Serv. 2002 Jul; 53 7 ; : 842-7. Review. PMID: 12096167 [PubMed - indexed for MEDLINE] 104: Blackmer J, Jefromova L. The use of alternative therapies in the Saskatchewan stroke rehabilitation population. BMC Complement Altern Med. 2002 Jul 2; 1 ; : Epub 2002 Jul 02. PMID: 12095423 [PubMed - indexed for MEDLINE] 105: Bean P. The use of alternative medicine in the treatment of hepatitis C. Clin Lab. 2002 May; 21 4 ; : 19-21. Review. PMID: 12087634 [PubMed - indexed for MEDLINE] 106: Wetzel BJ, Nindl G, Swez JA, Johnson MT. Quantitative characterization of rat tendinitis to evaluate the efficacy of therapeutic interventions. Biomed Sci Instrum. 2002; 38: 157-62. PMID: 12085595 [PubMed - indexed for MEDLINE] 107: Garrison HG, Maio RF, Spaite DW, Desmond JS, Gregor MA, O'Malley PJ, Stiell IG, Cayten CG, Chew JL Jr, Mackenzie EJ, Miller DR. Emergency Medical Services Outcomes Project III EMSOP III ; : the role of risk adjustment in out-of-hospital outcomes research. Ann Emerg Med. 2002 Jul; 40 1 ; : 79-88. Review. PMID: 12085077 [PubMed - indexed for MEDLINE] 108: Eichholz AC, Mahavni V, Sood AK. Allopathic and complementary alternatives to hormone replacement therapy. Expert Opin Pharmacother. 2002 Jul; 3 7 ; : 949-55. Review. PMID: 12083994 [PubMed - indexed for MEDLINE] and vasotec and tiazac, for example, atenolol. Tiazac oralEffective February 15, 2002, the following medications were removed from the HNE Formulary. These medications will now require the member to pay the highest Tier 3 ; copayment. Amerge naratriptan ; Formulary Alternatives: Imitrex Zomig Beclovent beclomethasone inhalation ; Formulary alternatives: Aerobid Flovent Qvar Vanceril Beconase Beconase AQ beclomethasone intranasal ; Formulary alternatives: Nasacort Nasacort AQ Rhinocort Rhinocort Aqua Vancenase Vancenase AQ Mavik trandolapril ; Formulary Alternatives: Accupril captopril generic ; enalapril generic ; Univasc Zestril Patanol olopatadine ophthalmic ; Formulary alternatives: Optivar Zatidor Tiazac diltiazem SR ; Formulary alternatives: Generic diltiazem products and verapamil. Narcotics Long Acting Avinza Duragesic Kadian Morphine Sulfate Tablet SA Oramorph SR OxyContin Narcotics Long Acting Drugs Requiring MEDICAL JUSTIFICATION MS Contin Oxycodone Tabs.SR 12H generic ; Non-Dihydropyridine Calcium Channel Blockers NDHPCCB ; Cartia XT generic of Cardizem CD ; Diltiazem, Diltiazem ER Generic of Cardizem and Cardizem CD ; Diltiazem SR generic of Cardizem SR ; Diltiazem XR generic of Dilacor XR ; Diltia XT generic of Dilacor XR ; Vascor Bepridil ; Non-Dihydropyridine Calcium Channel Blockers NDHPCCB ; Drugs Requiring MEDICAL JUSTIFICATION Cardizem * Cardizem CD * Cardizem LA Cardizem SR * Dilacor XR * Tiazac * Taztia XT generic of Tiazac ; Non-Ergot Dopamine Receptors Mirapex Requip Ophthalmic Antihistamines Patanol Ophthalmic antihistamines Drugs Requiring MEDICAL JUSTIFICATION Elestat Emadine Livostin Optivar Zaditor. Nosocomial exposure to HIV infection is best managed in consultation with an expert with experience in treating HIV. The sero-status of the source patient should be established. HIV, HBV HCV serology an RPR should be sent. Awaiting serologic test results of source patients who have limited risk of HIV infection, prophylaxis for injured workers can be delayed until results are obtained. For high risk exposures to source patients with known or suspected HIV, therapy should begin immediately. Risk of transmission based on exposure should be determined HIGH: percutaneous stick with hollow bore needle containing blood, pleural fluid, peritoneal fluid or CSF, or an exposure of an open wound to these fluids. INTERMEDIATE: exposure of mucous membranes or eyes with blood or body fluids that have high levels of HIV. LOW: any other type of exposure. Examples include blood on intact skin, exposures to urine, stool or saliva. HIGH RISK exposures should receive prophylaxis. Burkina Faso: The conservation of the biological diversity priority domain of the Agreement on Biological Diversity ; , in a Sahelian country as Burkina Faso, cannot be conceived separately from a coherent program to fight desertification Agreement on Combating Desertification ; . Also, fighting against desertification in an arid or semi-arid zone cannot be conceived without a sound water management policy Ramsar Convention ; . The water resources are themselves dependent upon the climactic risks Agreement on the Climactic Changes ; . Recent droughts and desertification severely affecting agricultural activities, population distribution, and the economy, overgrazing, soil degradation, deforestation. Mexico: Recommendations on ecological management and planning of land resources and climatic change with 35 items were established. The main obstacle that the CCDSs faces in Mexico is that the local authorities identify the CCDS as groups of environmentalists, exclusively. Therefore their analytical work about the relationships between the government, legislative, non-governmental, business, social and academic actors, is not considered by the local authorities. Scarcity of hazardous waste disposal facilities; rural to urban migration; natural fresh water resources scarce and polluted in north, inaccessible and of poor quality in center and extreme southeast; raw sewage and industrial effluents polluting rivers in urban areas; deforestation; widespread erosion; desertification; deteriorating agricultural lands; serious air and water pollution in the national capital and urban centers along US-Mexico border; land subsidence in Valley of Mexico caused by groundwater depletion. Philippines: Uncontrolled deforestation in watershed areas; soil erosion; air and water pollution in Manila; increasing pollution of coastal mangrove swamps that are important fish breeding grounds. Agreements: Biodiversity, Climate Change, Desertification, Endangered Species, Hazardous Wastes, Law of the Sea, Marine Dumping, Nuclear Test Ban, Ozone Layer Protection, Ship Pollution, Tropical Timber 83, Tropical Timber 94, Wetlands signed, but not ratified: Climate Change-Kyoto Protocol These two variables also cause a negative chain of reactions in the social and natural fabric of Philippine life - tenurial problems, denudation of eco-system and watershed areas, soil erosion, siltation, and the breakdown in food chain checks and balances. Concrete manifestations of these problems are reflected in the following indicators: 1. Forest cover on the Philippines has been reduced from more than 50% to less than 24. Boletn C-10 "Instrumentos financieros derivados y operaciones de cobertura" "C-10" ; . El C-10 requiere el reconocimiento de todos los derivados a valor razonable, establece reglas para el reconocimiento de operaciones de cobertura, as como para identificar y separar, en su caso, a los derivados implcitos. El C-10 establece para las coberturas de flujo de efectivo, que la porcin efectiva se reconoce en forma transitoria en la utilidad integral dentro del capital contable, y posteriormente se reclasifica a resultados al momento en que la partida cubierta los afecta; la porcin inefectiva se reconoce de inmediato en los resultados del periodo. Bajo la normatividad contable anterior Boletn C-2, "Instrumentos financieros" ; , hasta el 2004 la Compaa reconoca el efecto de los derivados de cobertura hasta que se efectuaban los intercambios de flujos estipulados del "swap", dentro del gasto financiero de los pasivos asociados. El efecto principal al 31 de diciembre de 2005 por la aplicacin de este nuevo pronunciamiento, fue el reconocimiento de un pasivo por instrumentos financieros derivados por , 176, con cargo al costo integral de financiamiento por , 217 y un cargo al resultado integral dentro del capital contable por , 959. Boletn D-3, Obligaciones laborales "D-3" ; , relativa al reconocimiento del pasivo por indemnizaciones por terminacin de la relacin laboral por causas distintas de reestructuracin, las cuales se registran conforme al mtodo de crdito unitario proyectado, con base en clculos efectuados por actuarios independientes. El D-3 permite la opcin de reconocer en forma inmediata en los resultados del ejercicio el activo o pasivo de transicin que resulte, o su amortizacin de acuerdo a la vida laboral remanente promedio de los trabajadores. Hasta 2004, las indemnizaciones por este concepto se cargaban a los resultados cuando se tomaba la decisin de pagarlas. El pasivo acumulado al 1 de enero de 2005, determinado por actuarios independientes, asciende a , 996, que la Compaa opt por registrarlo de inmediato con cargo a un activo intangible y un cargo a los resultados del ejercicio 2005, en el rubro efecto acumulado por cambio en principios de contabilidad, neto del efecto de impuesto sobre la renta cuyo monto ascendi a , 336. Tambin a partir del 1 de enero de 2004, la Compaa adopt las disposiciones del nuevo Boletn C-12 "Instrumentos financieros con caractersticas de pasivo, de capital o de ambos". La adopcin de este nuevo principio contable, no tuvo efectos importantes en su situacin financiera y resultados de la Compaa, because ibuprofen. Malities, and development of heart failure if started too aggressively in patients with preexisting left ventricular dysfunction.6, 22, 23 Beta blockers should be tapered before discontinuation to minimize the risk of reflex tachycardia. The effects of beta blockers on lipid profiles are transient and of little clinical significance.25 Beta blockers should be used with caution in combination with other negative chronotropes, such as diltiazem Cardizem CD, Dilacor XR, Tiazac ; , verapamil Isoptin SR, Calan SR ; , or digoxin.6, 22, 23 and tobradex. Likewise, diagnoses, along with an idea due what needs fact that benzodiazepines are tiazac known. 25. J.A.F. de Silva and M.A. Brooks in Drug Fate and Metabolism Vol. 2, E. K. Garrett Ed. United research laboratories watson pharma, inc. Type of seizures Intervention 2 Combination of partial generalised LTG; 200 mg day; 26 weeks Mean age age range No. randomised: 111 LTG 100 mg: 33 years; LTG Source No. completed: 76 200 mg: 30 years; CBZ: 32 years Literature search SD not stated LTG 100 mg: Comparator 1372 years; LTG 200 mg: Aim CBZ; 600 mg day; 1266 years; CBZ: 1371 years The efficacy and safety of LTG and CBZ as 26 weeks monotherapy in patients with untreated, newly No. randomised: 117 Gender diagnosed or recurrent partial and or GTC No. completed: 76 LTG 100 mg n 115 ; : seizures were compared in a randomised, men 54%, women 46%; open, multicentre study LTG 200 mg n 111 ; : men 58%, women 42%; Type of publication CBZ n 117 ; : men 50%, Full paper final analysis ; women 50% Funding Age at onset of seizures GlaxoSmithKline Age at onset LTG 100 mg n 115 ; : mean 29 years Trial ID range 071 years LTG 200 mg LAM30025 n 111 ; : mean 26 years range 161 years CBZ Study design n 117 ; : mean 28 years Monotherapy; new vs old; parallel trial; 170 years ; superiority trial Pretrial medication Not stated Ongoing concurrent medication Not stated. |
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
|
© 2005-2007 Www.thenaturalpower.info, Inc. All rights reserved. |
||||||||||||||||||||||||||||||||||||||||||||||